Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection

NCT04483674 is registered in ClinicalTrials.gov with Anna Cruceta as lead sponsor.

NCT NCT04483674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04483674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bictegravir/FTC/TAF for the Treatment of Primary HIV Infection
Lead sponsor
Anna Cruceta
Phase
Phase 2
Overall status
Unknown status
Start date
December 4, 2020
Completion date
June 30, 2023
Enrollment
66 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv primary infection